HORIBA Jobin Yvon Announces Acquisition of GenOptics

HORIBA Jobin Yvon (Longjumeau, France) a fully owned affiliate of HORIBA Ltd (Kyoto, Japan) and a leader in analytical instrumentation products and worldwide leader in optical spectroscopy, announced today, April 17th, 2009 the acquisition of GENOPTICS (Orsay, France). GENOPTICS will join the HORIBA Scientific business segment.

GENOPTICS specializes on bio-interactions label free detection and multiplex Surface Plasmon Resonance imaging. Label free detection and SPRi are important for bio affinity investigation as they provide a novel high throughput technique for ligand fishing and screening of peptides, antibodies, proteins and even cells.

Label free bio-interactions detection is becoming increasingly important in meeting the needs of life science researchers. "In the coming years we will see the merging of biotechnology and microtechnology to create combinations of ultra integrated devices on a molecular scale" states Dr. Michel Mariton HORIBA Scientific segment leader. "The acquisition of GenOptics is a part of HORIBA Scientific's commitment to play a leading role in this important and exciting new field."

"In addition, the increasing use of multiplexed biochips as disposable resources, will allow cost effective multiple and fast bio-markers screening" comments Dr Chiraz Frydman HORIBA Scientific Life Science product manager.

"Becoming a part of the HORIBA Scientific biotechnology platform clearly validates the competitive edge of our development capabilities and the quality of our instrument portfolio. Together we will develop next-generation products for the market. The integration will allow GENOPTICS, to reach an industrial stage and accelerate its development ..." adds P. Kerouredan, former CEO of GENOPTICS.

Previously in January 2007, HORIBA Jobin Yvon and Genoptics signed an international distribution and service agreement. The acquisition now secures HORIBA Scientific full access to additional polarized light imaging techniques and to all research and development options of the company that were not yet included in the agreement.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback